Evidence map›Paper›PMID 42861395›Full record

ArticleiScience2026

DeepNPA: A protBert-based framework for residue-level annotation of neuropeptide precursors.

Xin-Yu Li, Yang Yu, Li-Ping Liu, Meng-Ze Du, Qiang Tang, Juan-Juan Kang

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin-Yu LiSchool of Intelligent Medicine, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Yang YuSchool of Intelligent Medicine, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Li-Ping LiuState Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Meng-Ze DuSchool of Healthcare Technology, Chengdu Neusoft University, Chengdu 611844, China.
Qiang TangKey Laboratory of Non-coding RNA and Drug Discovery at Chengdu Medical College of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu 610500, China.
Juan-Juan KangSchool of Intelligent Medicine, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropeptides are key signaling molecules that regulate the nervous and endocrine systems, and their maturation depends on precise proteolytic cleavage of precursor proteins. However, residue-level annotation remains essential yet experimentally labor intensive, with limited dedicated computational tools. Here, we present DeepNPA, a residue-level annotation framework that integrates ProtBert, a pretrained protein language model, with focal loss for imbalance-aware optimization. DeepNPA was trained and evaluated on a non-redundant Swiss-Prot-derived dataset annotated using the BIO scheme. On a held-out test dataset, DeepNPA achieved strong performance, with an accuracy of 0.953, an F1-score of 0.927, and an AUPRC of 0.965. On an independent benchmark dataset, DeepNPA outperformed NeuroCS and NeuroPred, achieving an ACC of 0.969 and Matthews correlation coefficient (MCC) of 0.666. External validation further demonstrated its ability to identify neuropeptide regions and their associated cleavage sites. In addition, we provided an online prediction platform to facilitate neuropeptide precursor annotation and cleavage site analysis.

Indexed as

cleavage site predictionfocal lossneuropeptide precursorProtBertresidue-level annotation

Identifiers

PMID42861395
PMCPMC13654548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.